ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy
暂无分享,去创建一个
H. Schlüter | G. Sauter | T. Schlomm | C. Bokemeyer | R. Simon | S. Minner | M. Graefen | T. Steuber | A. Luebke | K. Pantel | U. Schumacher | Alvin Y. Liu | Julia Müller | H. Sirma | P. Tennstedt | A. Krohn | Pascale S Mayer | J. C. Brase | L. Scholz | Malaika Enodien
[1] G. Sauter,et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. , 2011, Human pathology.
[2] M. Rubin,et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.
[3] A. Haese*,et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.
[4] M. Rubin,et al. Single focus prostate cancer: pathological features and ERG fusion status. , 2011, The Journal of urology.
[5] M. Rubin,et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. , 2010, Neoplasia.
[6] Asha A. Nair,et al. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. , 2010, Cancer research.
[7] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[8] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[9] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[10] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[11] Hartwig Huland,et al. Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.
[12] G. Sauter,et al. Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.
[13] I. Sesterhenn,et al. Clinicopathological behavior of single focus prostate adenocarcinoma. , 2009, The Journal of urology.
[14] M. Rubin,et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.
[15] R. Shah,et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.
[16] M. Gerstein,et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. , 2009, Neoplasia.
[17] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[18] M. Rubin,et al. INTEGRATION OF ERG GENE MAPPING AND GENE‐EXPRESSION PROFILING IDENTIFIES DISTINCT CATEGORIES OF HUMAN PROSTATE CANCER , 2009, BJU international.
[19] C. Sander,et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.
[20] Pier Paolo Pandolfi,et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.
[21] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[22] John M S Bartlett,et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. Gerald,et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.
[24] Martin Schostak,et al. Expression and prognostic relevance of annexin A3 in prostate cancer. , 2008, European urology.
[25] O. Ludkovski,et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.
[26] G. Sauter,et al. Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients , 2008, Clinical Cancer Research.
[27] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[28] S. Dhanasekaran,et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.
[29] M. Gleave,et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer , 2008, BMC Cancer.
[30] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[31] T. Tammela,et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.
[32] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[33] A. Chinnaiyan,et al. Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.
[34] J. Trachtenberg,et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.
[35] Yao-Tseng Chen,et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.
[36] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[37] J. Damber,et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. , 2007, Oncology reports.
[38] J. Tchinda,et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. , 2007, Neoplasia.
[39] L. Klotz,et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.
[40] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.
[41] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[42] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[43] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[44] J. Gromada,et al. Sterol regulatory element-binding protein 1 mediates liver X receptor-beta-induced increases in insulin secretion and insulin messenger ribonucleic acid levels. , 2006, Endocrinology.
[45] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[46] J. Cheville,et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.
[47] Biaoyang Lin,et al. The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[48] M. Graefen,et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.
[49] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[50] W. Folk,et al. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. , 2001, European journal of cancer.
[51] L. Hood,et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.
[52] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.